Colorectal Cancer

Latest News

ctDNA analysis | Image credit: Thaweechai - stock.adobe.com
ctDNA Response Predicts Outcomes in MSI-H mCRC Immunotherapy

June 18th 2025

Early circulating tumor DNA (ctDNA) changes predict survival in mismatch repair or microsatellite instability–high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs).

FIT test CRC - Paul Maguire - stock.adobe.com
Starting Colorectal Cancer Screening at Age 40 Cuts Death Risk by 39%, Study Finds

June 12th 2025

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com
Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

June 6th 2025

CRC detection | Image credit: Ahmet Aglamaz - stock.adobe.com
Blood Test Detects 79% of Colorectal Cancers in Screening Study

June 3rd 2025

The authors emphasized the need for further research into improving the diagnostic performance of both blood- and stool-based tests, particularly to enhance early lesion detection. | Image credit: SewcreamStudio - stock.adobe.com
FIT Outperforms Blood-Based cfDNA Test in Detecting Precancerous Colorectal Lesions

May 31st 2025

More News

Colon Cancer | Image credit: SciePro - stock.adobe.com
December 12th 2023

Novel Comprehensive Blood Indicator Potential Prognostic Factor for CRC

Julia Bonavitacola
Predicting clinical outcomes in patients with colorectal cancer (CRC) could be done using the novel comprehensive blood indicator PSI.
Incidence of CRC Increased in Male Patients Younger Than 50 Years
December 7th 2023

Incidence of CRC Increased in Male Patients Younger Than 50 Years

Julia Bonavitacola
Although the incidence of colorectal cancer (CRC) decreased in individuals older than 50 years, incidence of CRC increased in male individuals younger than 50 years.
Potential Link Exists Between Constipation, Colorectal Cancer
December 5th 2023

Potential Link Exists Between Constipation, Colorectal Cancer

Julia Bonavitacola
A Mendelian randomization found that a potential link between constipation and colorectal cancer, with support for constipation as a cause of colorectal cancer.
Aesthetic handdrawn highlighted illustration of human intestine | Image credit: mi_viri - stock.adobe.com
November 27th 2023

Screening Associated With Overall Survival After Metachronous Metastasis in CRC

Julia Bonavitacola
Patients with colorectal cancer (CRC) who had diagnosed metachronous metastasis had longer overall survival when the primary tumor was detected through screening.
Dark blue ribbon for colon - colorectal cancer awareness on medical doctor's hand support | Image credit: Chinnapong - stock.adobe.com
November 21st 2023

FIT Screening Found to Be Unsatisfactory in 10% of Submitted Tests

Julia Bonavitacola
More than 10% of fecal immunochemical test (FIT)–based colorectal cancer screening could not be processed due to unsatisfactory samples.
Unrecognizable female doctor holding graphic virtual visualization model of Intestine organ in hands | Image credit: mi_viri - stock.adobe.com
November 13th 2023

28-Day Mortality Predicted by Machine Learning in Patients With CRC

Julia Bonavitacola
Critically ill older patients with colorectal cancer (CRC) had their 28-day mortality predicted using machine learning algorithms.
Mailed Stool Tests Increased CRC Screening in Systemwide Program
November 10th 2023

Mailed Stool Tests Increased CRC Screening in Systemwide Program

Julia Bonavitacola
The implementation of a mailed stool test program increased colorectal cancer (CRC) screen-up-to-date rates compared with lower-intensity interventions, such as patient letters.
FDA Approved | Image credit: Olivier Le Moal - stock.adobe.com.jpg
November 9th 2023

FDA Approves Fruquintinib for Metastatic Colorectal Cancer

Gina Mauro
The FDA has approved fruquintinib (Fruzaqla) for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
Higher Rate of Metastasis to Main Nodes in Transverse Colon Cancer
November 7th 2023

Higher Rate of Metastasis to Main Nodes in Transverse Colon Cancer

Julia Bonavitacola
Caecal cancer and ascending colon cancer had slower rates of metastasis to main nodes compared with transverse colon cancer.
Postoperative ctDNA Status May Prognosticate DFS Outcomes in Resected CRC
November 3rd 2023

Postoperative ctDNA Status May Prognosticate DFS Outcomes in Resected CRC

Courtney Flaherty
Postoperative circulating tumor DNA (ctDNA)–based minimal residual disease status demonstrated prognostic value for patients with stage 1 to 4 resected colorectal cancer, showing that those with positive ctDNA after surgery have significantly lower disease-free survival outcomes at 24 months vs those who were ctDNA negative.
Aesthetic handdrawn highlighted illustration of human intestine | Image credit: mi_viri - stock.adobe.com
November 1st 2023

Inflammatory Markers Have Prognostic Value in Patients With CRC

Julia Bonavitacola
Patients with colorectal cancer (CRC) can use C-reactive protein (CRP), lymphocyte to CRP ratio, and CRP to albumin ratio as markers for CRC prognosis.
Patients With High BMI, Diabetes Had Higher Risk of Infection After Colorectal Surgery
October 27th 2023

Patients With High BMI, Diabetes Had Higher Risk of Infection After Colorectal Surgery

Julia Bonavitacola
Patients who underwent surgery for colorectal cancer had a higher risk of postoperative infection if they had high body mass index (BMI) or diabetes, among other risk factors.
Metabolic Dysregulation Could Contribute to Incidence of Colorectal Serrated Lesions
October 24th 2023

Metabolic Dysregulation Could Contribute to Incidence of Colorectal Serrated Lesions

Julia Bonavitacola
The incidence of colorectal serrated lesions could be attributed to metabolic syndrome, which causes metabolic dysregulation.
FDA Approves RAS Mutation Detection Kit as Companion Diagnostic for Panitumumab in mCRC
October 20th 2023

FDA Approves RAS Mutation Detection Kit as Companion Diagnostic for Panitumumab in mCRC

Chris Ryan
The FDA has approved the CRCdx RAS Mutation Detection Kit as a companion diagnostic for panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC), according to an announcement from EntroGen.
Webinar Highlights Recommendations to Improve Disparities in CRC Screening
October 18th 2023

Webinar Highlights Recommendations to Improve Disparities in CRC Screening

Julia Bonavitacola
Experts in colorectal cancer (CRC) discussed the new health recommendations from the Network for Excellence in Health Innovations report and how they apply to the disparities in screening for CRC.
Clinical Staging of Colorectal Cancer Increased in Post–COVID-19 Period
October 12th 2023

Clinical Staging of Colorectal Cancer Increased in Post–COVID-19 Period

Julia Bonavitacola
Significant increases in clinical staging for colorectal cancer were found when evaluating the extended timeframes beyond pre– and post–COVID-19 periods.
Video Intervention Increased CRC Screening in Somali-Speaking Patients
October 9th 2023

Video Intervention Increased CRC Screening in Somali-Speaking Patients

Julia Bonavitacola
Patients who spoke Somali were more willing to get a screening for colorectal cancer (CRC) after a video intervention.
In-Person Interactions Key to Improve CRC Screening Rates in African American Individuals
October 6th 2023

In-Person Interactions Key to Improve CRC Screening Rates in African American Individuals

Julia Bonavitacola
Successfully increasing colorectal cancer screening rates in African Americans could be achieved through the key roles of in-person interactions and community contexts.
Symptom Distress, Depression, Lower Social Support Found in Younger Patients With CRC and Stoma
October 3rd 2023

Symptom Distress, Depression, Lower Social Support Found in Younger Patients With CRC and Stoma

Julia Bonavitacola
Younger patients who had colorectal cancer (CRC) stoma had more symptom distress, were depressed and anxious, and had higher supportive care needs.
Low Exercise, Sarcopenia, Myosteatosis Associated With CRC-Specific Mortality
September 30th 2023

Low Exercise, Sarcopenia, Myosteatosis Associated With CRC-Specific Mortality

Julia Bonavitacola
Sarcopenia or myosteatosis combined with low prediagnostic physical exercise was associated with increased mortality from colorectal cancer (CRC).
Novel mRNA Biomarker Integration Boosts Sensitivity, Specificity of ColoAlert in Detecting CRC
September 28th 2023

Novel mRNA Biomarker Integration Boosts Sensitivity, Specificity of ColoAlert in Detecting CRC

Chris Ryan
The integration of novel mRNA biomarkers into the ColoAlert screening test resulted in high sensitivity and specificity for detecting colorectal cancer (CRC).
Nofazinlimab Not Associated With Response in mCRC When Combined With Regorafenib
September 26th 2023

Nofazinlimab Not Associated With Response in mCRC When Combined With Regorafenib

Julia Bonavitacola
Although nofazinlimab was well tolerated and showed antitumor activity in many tumor types, no response was found when combined with regorafenib to treat metastatic colorectal cancer (mCRC).
Unmeasured Social Context Could Explain Racial Differences in Screening for CRC
September 19th 2023

Unmeasured Social Context Could Explain Racial Differences in Screening for CRC

Julia Bonavitacola
Screening for colorectal cancer (CRC) is defined by racial differences, which could be explained through social context.
Prevalence, Incidence of Early-Onset CRC Increased in Individuals Aged 40 to 49 Years
September 18th 2023

Prevalence, Incidence of Early-Onset CRC Increased in Individuals Aged 40 to 49 Years

Julia Bonavitacola
Although mortality and disability-adjusted life-years remained stable, the prevalence and incidence of early-onset colorectal cancer (CRC) increased globally in individuals aged 40 to 49 years.
FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC
September 15th 2023

FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC

Caroline Seymour
The FDA has granted 2 breakthrough therapy designations to trastuzumab deruxtecan for the treatment of patients with unresectable or metastatic HER2-positive solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, and for those with HER2-positive metastatic colorectal cancer who have received at least 2 prior lines of therapy.
Man waist measured
September 7th 2023

Visceral Obesity Associated With Anastomotic Leakage After Colon Cancer Surgery

Julia Bonavitacola
A significant relationship between visceral obesity and anastomotic leakage was found, which indicates that visceral obesity could be a risk factor in surgery for colon cancer.
tumor cell
September 4th 2023

Postoperative ctDNA Provides Prognostic Value for DFS Outcomes in CRC

Kyle Doherty
Circulating tumor DNA (ctDNA) status at the time of postoperative minimal residual disease assessment is a prognostic factor for disease-free survival (DFS) in patients with radically resected stage II to IV colorectal cancer (CRC).
Illustrated colorectal image | Credit: mi_viri - stock.adobe.com
August 28th 2023

HER2 Amplification Shows Prognostic Capabilities in mCRC

Megan Hollasch
Although HER2 amplification showed prognostic capabilities in patients with RAS wild-type metastatic colorectal cancer (mCRC), it was not predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.
Doctor projects the human large intestine on the tablet. Study and analysis of colon cancer, bacteria, inflammation, ulcerative colitis, colonoscopy, diverticulosis. Health technology development: © Tom - stock.adobe.com
August 25th 2023

Personalized CRC Screening Remains Elusive, Requires Careful Planning

Maggie L. Shaw
Three sessions of a semi-structured focus group were conducted to gain patient feedback on personalized screening for colorectal cancer (CRC).
paper people of different colors
August 18th 2023

Time to Treatment Initiation Affected by Demographics, Socioeconomics in CRC, NSCLC

Kyle Doherty
Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of time to treatment initiation.
<1234567>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo